Vish Muthusamy

Vish Muthusamy is a Research Scientist at Yale School of Medicine with appointments in the Department of Medical Oncology and Hematology and the Developmental Therapeutics Program. He serves as the Director of the Center for Precision Cancer Modeling at Yale Cancer Center, where he focuses on advancing candidate therapeutic agents toward clinical application.

Dr. Muthusamy is a cancer biologist with expertise spanning multiple disciplines:

• Cancer genetics and epigenetics
• Immunobiology and immunotherapy
• Pharmacological development of anti-cancer drugs
• Preclinical modeling and testing

His research program focuses on understanding genetic alterations that drive cancer formation and progression, developing in vivo tumor models, and translating these findings into therapeutic approaches. Dr. Muthusamy frequently collaborates with medicinal chemists and has worked with both large and small pharmaceutical companies to develop therapeutic agents targeting cancer, infectious pathogens, and immune disorders. As Director of the Center for Precision Cancer Modeling, he plays a key role in Yale's translational research ecosystem, helping investigators bridge the gap between laboratory discoveries and clinical applications.

Dr. Muthusamy's publication record demonstrates a strong trajectory from basic cancer biology to translational drug development. His recent work (2023-2025) focuses on overcoming checkpoint inhibitor resistance through novel immunotherapies, including IL-12 mRNA therapy and CD40 agonists. Earlier work (2016-2022) includes research on targeted therapies for specific cancer types like FGFR3-driven bladder cancer, metabolic isozyme targets in cancer, and innovative approaches to protein degradation and immune recruitment.

Dr. Muthusamy maintains active collaborations across Yale and with external partners. His frequent co-authors include Katerina Politi, Marcus Bosenberg, Akiko Iwasaki, Anna Marie Pyle, and Daniel P. Petrylak, indicating strong connections across cancer biology, immunology, and clinical oncology disciplines.

As Director of the Center for Precision Cancer Modeling, Dr. Muthusamy leads a research team focused on preclinical development of cancer therapeutics. The center provides expertise in developing and validating tumor models that better predict clinical response, helping Yale researchers advance their discoveries toward clinical trials and eventual patient care.